Abstract:Abstract 2528 Background: Minimal residual disease(MRD) is currently the most powerful prognostic indicator in childhood ALL as well as in adult ALL. Using neonatal NOD/SCID/IL2rγnull xenotransplantation model, we previously demonstrated that CD34+CD38+CD19+ cells as well as CD34+CD38−CD19+ cells have the capacities to initiate B-ALL in vivo and to self-renew, that is, CD34+CD19+ cells are leukemia initiating cells(LICs) in human B-precursor ALL (B-ALL)(Kong Y et al. Leukemia 2008; 22: 1207–1213). Nevertheless, immunophenotypic differences between B-ALL initiating cells and normal progenitor B cells have not been clearly clarified. Especially, whether the LICs identified in xenotransplantation assay are clinically useful for routine MRD monitoring in B-ALL patients is largely unknown. Objective: To compare phenotypic characteristics of LICs in B-ALL patients to that of normal progenitor B cells in healthy donors. To evaluate clinical significances of LICs as novel MRD markers in predicting relapses in human B-precursor ALL. Materials and methods: To identify new markers for MRD detection in B-ALL, we compared phenotypic characterization of LICs from 40 patients with newly diagnosed B-ALL and 40 patients with relapsed B-ALL to that of normal progenitor B cells from 40 healthy donors by seven-color flow cytometry (FCM). Comparative analysis was performed at mean fluorescence intensity (MFI) of CD38, CD45, CD58 and CD123 on CD34+CD19+ cells among the above three groups. Subsequently, the most promising markers were examined in detail for their usefulness as MRD markers by seven-color FCM at different time points in 823 patients (including pediatric and adult patients) with B-ALL from January 2010 to June 2011 at Peking University Institute of Hematology. A total of 1,050,000 events were routinely collected. More than 0.001% of LICs with aberrant highly expression of CD123 and/or CD58 in bone marrow samples detected by seven-color FCM were defined as FCM positive (FCM+). FCM positivity at any time was defined as MRD positive (FCM MRD+), all others cases were defined as MRD negative (FCM MRD−). Real-time quantitative polymerase chain reaction (RQ-PCR) was applied concurrently to evaluate MRD in Philadelphia chromosome positive ALL (Ph+ ALL) patients. The value of BCR/ABL equal to 0 was defined as RQ-PCR negative (RQ-PCR-). The results of MRD studies by the two methods were recorded independently. Results: MFI of CD58(3.46±1.85 vs.3.82±1.83 vs.1.35±0.77, p <0.001) and CD123(6.37±3.47 vs.7.56±3.90 vs. 3.66±1.94, p <0.001) was significantly higher on LICs from newly diagnosed B-ALL and relapsed B-ALL than that of their normal counterparts. Meanwhile, MFI of CD38(8.09±6.36 vs.11.23±8.59 vs. 37.89±7.91, p <0.05) and CD45(7.42±5.14 vs.9.91±7.72 vs.13.50±8.20, p <0.05) was significantly lower on LICs than that of their normal counterparts. Further ANOVA analysis by LSD method demonstrated MFI of CD38, CD45, CD58 and CD123 on LICs differed significantly from that of normal progenitor B cells, whereas the phenotypic differences on LICs from newly diagnosed B-ALL or relapsed B-ALL showed no statistically significance. In the sequential MRD follow up, 185 samples from110 cases of B-ALL were detected as FCM MRD+. Among them, LICs from 56 cases(51%) with aberrant highly CD58 expression, 106 cases(96%) with aberrant highly CD123 expression and 40 cases(36%) with simultaneously aberrant highly expressions of CD58 and CD123. Twenty-two cases relapsed during MRD monitoring, of them 19 cases were detected as FCM MRD+ at a median time of 57 days (13–90days) before their recurrence. The left 3 relapsed cases did not monitor MRD status for about 3 months as we expected. MRD analysis was performed concurrently by both RQ-PCR and FCM in 85 follow-up bone marrow samples from 23 Ph+ ALL patients. A good correlation was found between RQ-PCR and FCM (Spearman r=0.883, p < 0.001). Conclusions: Mean fluorescence intensity of CD38, CD45, CD58 and CD123 antigens distinguished B-ALL initiating cells from their normal counterparts, CD34+CD19+ normal progenitor B cells. The B-ALL initiating cells with aberrant highly expression of CD123 and/or CD58 detected by seven-color FCM may serve as promising markers for MRD monitoring in B-ALL. Disclosures: No relevant conflicts of interest to declare.

CD34+CD38+CD19+ As Well As CD34+CD38−CD19+ Cells Are Leukemia-Initiating Cells with Self-Renewal Capacity in Human B-precursor ALL

CD34+CD38-CD58- Candidate Leukemia-Initiating Cells Are Clinically Relevant with the Unfavorable Prognosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia.

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized

CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study

Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

Multiple cells of origin in common with various types of mouse N-Myc acute leukemia

[Establishment of Human Acute B-lymphoblastic Leukemia NOD/SCID/IL2 Receptor Γ Chain(null) Neonatal Mouse Xenotransplant Model].

Leukemia Initiating Cells: New Markers for Minimal Residual Disease Monitoring in B-Precursor Acute Lymphoblastic Leukemia

[In Vitro Identification and Characteristics of CD34- Leukemia Stem Cell in T(8;21) Acute Myeloid Leukemia].

Initial Frequency of CD34+/CD38 − Cells is Not Correlated with Minimal Residual Disease Level in 73 Chinese Children with B-cell Precursor Acute Lymphoblastic Leukemia

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia

Successful engraftment of human acute lymphoblastic leukemia cells in NOD/SCID mice via intrasplenic inoculation

N-Cadherin and Tie2 Positive CD34+CD38−CD123+ Leukemic Stem Cell Populations Can Develop Acute Myeloid Leukemia More Effectively in NOD/SCID Mice

Cd34(+)Cd38(-)Cd58(-) Leukemia-Propagating Cells At Diagnosis Could Identify Patients At High-Risk For Relapse In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

New Insight of Leukemic Stem Cell

Single-cell RNA-seq analysis revealed the stemness of a specific cluster of B cells in acute lymphoblastic leukemia progression